Join the DayOne Healthtech Investor Community

The DayOne Accelerator supports international healthtech startups across the innovation spectrum, helping them navigate early-stage challenges, secure funding and scale. Through tailored support, access to industry leaders, seasoned mentors, and a robust network of partners and investors, the program empowers startups to refine their strategy and accelerate growth.

Over the course of three months, participants sharpen their value propositions, engage with key players in the life sciences ecosystem, and position themselves for long-term success. Top-performing startups may receive follow-on funding and extended support.

The program is based in Basel, Switzerland – Europe’s leading hub for life sciences innovation.

DayOne is a non-profit organisation, supported by a blend of public and private funding. The program does not take equity in the startups (during or after the accelerator).

Backed by the Basel-Stadt Kanton and operating under the umbrella of Basel Area Business and Innovation, DayOne offers lasting stability and strong public-sector support.

The DayOne program targets startups in digital health, medtech and techbio that are developing solutions for pharma R&D. We focus on companies from Pre-Seed to Series A stage that have raised under $10m in dilutive funding and are seeking collaboration or partnership with major pharmaceutical players. Our portfolio is globally diverse, with alumni from Europe, Asia and North America.

Our investor community includes venture capital firms, corporate VCs, business angels and family offices. We seek investors with an active interest in healthtech – ideally with a dedicated fund or portfolio – and a focus on Pre-Seed to Series A investments. While our network is global, most investors backing our startups are based in Switzerland, the EU, the UK and the US.

The DayOne Accelerator is a three-month hybrid program designed to connect healthtech startups with key pharma and medtech leaders. It offers one-on-one mentorship from senior industry executives, expert-led learning sessions, investor connections, funding pathways, and pitch opportunities with industry partners.

In the 2024-2025 cohort, following the program, Theremia secured $3 million to enhance drug efficacy and development through their AI-driven platform, while Senseera raised $7.1 million to advance their liquid biopsy platform, aiming to transform diagnostics.

Only the most promising startups, selected from a large competitive pool, receive investment. Each opportunity is rigorously vetted through our accelerator program, ensuring a derisked, high-quality deal flow. DayOne takes no equity during or after the accelerator, focusing instead on long-term success and value creation. Backed by Basel-Stadt Kanton and operating under Basel Area Business and Innovation, DayOne provides stability and strong public support.

Investments are structured through convertible notes, offering downside protection and upside potential. Investors choose which startups to back and help shape the long-term support plans. The Basel ecosystem is an exceptional launchpad for R&D-driven ventures, offering access to customers, labs, talent, infrastructure and strategic exit opportunities. Our engagement continues beyond investment, with tailored mentorship, non-dilutive funding, network access, space at Switzerland Innovation Park and additional resources to support startups as they grow into valuable life science partners.

As an investor, you’ll gain access to a curated, actively managed pipeline of high-potential healthtech startups – enhancing deal flow and reducing investment risk. The program facilitates one-on-one meetings with ventures aligned to your interests and offers exclusive networking within the DayOne investor community, enabling co-investment opportunities.

DayOne acts as a facilitator and strategic matchmaker – connecting investors and industry partners with a curated selection of high-potential healthtech startups poised for market traction. Leveraging deep sector expertise and a clear understanding of industry challenges, we create streamlined, lower-risk investment and co-investment opportunities tailored for long-term impact.

As a founding investor, you’ll play an active role on the Accelerator selection committee alongside industry experts – giving you direct influence over which startups receive investment and how the long-term support program is shaped. You gain early access to the startups, enabling you to guide their development and ensure they are investment-ready within three months. You also receive expert evaluations from regulatory, IP, and legal partners, along with feedback from pharma executives, to support well-informed investment decisions.

Reach out to us directly here for more information.